CoChat

A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies

Open access
Dadgar, Neda, Gonzalez-Suarez, Alan M., Fattahi, Pouria, Hou, Xiaonan, Weroha, John S., Gaspar-Maia, Alexandre, Stybayeva, Gulnaz, Revzin, Alexander · 2020 · Microsystems & Nanoengineering

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

There is increasing interest in utilizing in vitro cultures as patient avatars to develop personalized treatment for cancer. Typical cultures utilize Matrigel-coated plates and media to promote the proliferation of cancer cells as spheroids or tumor explants. However, standard culture conditions operate in large volumes and require a high concentration of cancer cells to initiate this process. Other limitations include variability in the ability to successfully establish a stable line and inconsistency in the dimensions of these microcancers for in vivo drug response measurements. This paper explored the utility of microfluidics in the cultivation of cancer cell spheroids. Six patient-derived xenograft (PDX) tumors of high-grade serous ovarian cancer were used as the source material to demonstrate that viability and epithelial marker expression in the microfluidic cultures was superior to that of Matrigel or large volume 3D cultures. To further demonstrate the potential for miniaturization and multiplexing, we fabricated multichamber microfluidic devices with integrated microvalves to enable serial seeding of several chambers followed by parallel testing of several drug concentrations. These valve-enabled microfluidic devices permitted the formation of spheroids and testing of seven drug concentrations with as few as 100,000 cancer cells per device. Overall, we demonstrate the feasibility of maintaining difficul-to-culture primary cancer cells and testing drugs in a microfluidic device. This microfluidic platform may be ideal for drug testing and personalized therapy when tumor material is limited, such as following the acquisition of biopsy specimens obtained by fine-needle aspiration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41378-020-00201-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparison of OC cultivation with three different methods. a Culture methods for OC spheroids. Matrigel cultures established in 6-well plates coated with 100% Matrigel containing no microwells. Both standard and microfluidic cultures contained microwells of the same dimensions (250 μm diameter and 300 μm in depth) for spheroid formation. b An image of a microfluidic chamber containing an array of 19 microwells for spheroid formation. The array of spheroids was connected to media reservoirs via a transport channel. The dotted square shows the location of the microwells. Scale bar = 5 mm. c Schematic depicting seeding of cells and spheroid formation. The PDMS surface inside the device is functionalized by treatment with Pluronic F-127 to minimize cell-surface interactions and promote cell–cell interactions
Fig. 1 Comparison of OC cultivation with three different methods. a Culture methods for OC spheroids. Matrigel cultures established in 6-well plates coated with 100% Matrigel containing no microwells. Both standard and microfluidic cultures contained microwells of the same dimensions (250 μm diameter and 300 μm in depth) for spheroid formation. b An image of a microfluidic chamber containing an array of 19 microwells for spheroid formation. The array of spheroids was connected to media reservoirs via a transport channel. The dotted square shows the location of the microwells. Scale bar = 5 mm. c Schematic depicting seeding of cells and spheroid formation. The PDMS surface inside the device is functionalized by treatment with Pluronic F-127 to minimize cell-surface interactions and promote cell–cell interactionsCC BY · PubMed Central
Fig. 2 Cultivation of OC spheroids in a single chamber microfluidic device. a Micrographs showing microwell areas from a microfluidic device with spheroids after 7 and 14 days of culture (scale bar = 250 µm). The insert shows a zoomed-in image of a single microwell/spheroid (scale bar = 100 µm). The right image shows live/dead staining at day 14 (live (green), dead (red fluorescence)). b Viability of spheroids from the six PDX lines after 14 days of culture were tested in this study to compare microfluidic (gray bars) versus standard (black bars) culture methods. Live/dead staining was used for quantification (p < 0.05, n = 6). c Increase in spheroid diameter was observed after 14 days of culture (p < 0.05, n = 6)
Fig. 2 Cultivation of OC spheroids in a single chamber microfluidic device. a Micrographs showing microwell areas from a microfluidic device with spheroids after 7 and 14 days of culture (scale bar = 250 µm). The insert shows a zoomed-in image of a single microwell/spheroid (scale bar = 100 µm). The right image shows live/dead staining at day 14 (live (green), dead (red fluorescence)). b Viability of spheroids from the six PDX lines after 14 days of culture were tested in this study to compare microfluidic (gray bars) versus standard (black bars) culture methods. Live/dead staining was used for quantification (p < 0.05, n = 6). c Increase in spheroid diameter was observed after 14 days of culture (p < 0.05, n = 6)CC BY · PubMed Central
Fig. 3 Comparison of spheroid cultures on Matrigel and in microfluidic devices. a Micrographs showing cells from three different PDX lines cultured on Matrigel and in microfluidic microwells. Note the difference the uniform spheroid formation in microfluidic microwells with the variable spheroid sizes on Matrigel. No spheroids could be formed for PDX line PH592 on Matrigel. Scale bar = 250 µm. b Viability for cultures from all PDX lines at day 14 comparing microfluidic (gray bar) and Matrigel (black bar) culture conditions. Microfluidic cultures showed significantly better viability (p < 0.05, n = 6) for all PDX lines except for PH704
Fig. 3 Comparison of spheroid cultures on Matrigel and in microfluidic devices. a Micrographs showing cells from three different PDX lines cultured on Matrigel and in microfluidic microwells. Note the difference the uniform spheroid formation in microfluidic microwells with the variable spheroid sizes on Matrigel. No spheroids could be formed for PDX line PH592 on Matrigel. Scale bar = 250 µm. b Viability for cultures from all PDX lines at day 14 comparing microfluidic (gray bar) and Matrigel (black bar) culture conditions. Microfluidic cultures showed significantly better viability (p < 0.05, n = 6) for all PDX lines except for PH704CC BY · PubMed Central
Fig. 4 Phenotype assessment of OC spheroids. a A representative spheroid from a microfluidic device stained for an epithelial marker EpCAM and a proliferation marker Ki-67 as well as the nuclear dye DAPI. b PCR-RT results for the proliferation marker Ki-67 and epithelial markers PAX8, CK-7, and EpCAM. The results show similar or higher expression levels in microfluidic cultures compared to the standard culture method (p < 0.05, n = 3)
Fig. 4 Phenotype assessment of OC spheroids. a A representative spheroid from a microfluidic device stained for an epithelial marker EpCAM and a proliferation marker Ki-67 as well as the nuclear dye DAPI. b PCR-RT results for the proliferation marker Ki-67 and epithelial markers PAX8, CK-7, and EpCAM. The results show similar or higher expression levels in microfluidic cultures compared to the standard culture method (p < 0.05, n = 3)CC BY · PubMed Central
Fig. 5 A multichamber microfluidic device. a, b Pictures showing a microfluidic device in serial perfusion (a) and parallel testing (b) modes. In serial perfusion, the device is configured to connect culture chambers serially. All culture chambers in (a) are filled with blue dye. In parallel perfusion, the device is reconfigured to sequester individual culture compartments and infuse them with dyes of different colors (blue, yellow, green, and red). c–e Images showing spheroids formed after seeding 25,000 (c), 50,000 (d), and 100,000 (e) cells into the device. Scale bar: 300 µm. f A graph showing spheroid diameter as a function of inoculation concentration for the 8 chambers of the device. Chamber 1 is closest to the inlet used for cell seeding, and chamber 8 is furthest. Spheroids were measured 24 h after seeding (n = 8)
Fig. 5 A multichamber microfluidic device. a, b Pictures showing a microfluidic device in serial perfusion (a) and parallel testing (b) modes. In serial perfusion, the device is configured to connect culture chambers serially. All culture chambers in (a) are filled with blue dye. In parallel perfusion, the device is reconfigured to sequester individual culture compartments and infuse them with dyes of different colors (blue, yellow, green, and red). c–e Images showing spheroids formed after seeding 25,000 (c), 50,000 (d), and 100,000 (e) cells into the device. Scale bar: 300 µm. f A graph showing spheroid diameter as a function of inoculation concentration for the 8 chambers of the device. Chamber 1 is closest to the inlet used for cell seeding, and chamber 8 is furthest. Spheroids were measured 24 h after seeding (n = 8)CC BY · PubMed Central
Fig. 6 Drug treatment of cancer cells. a Drug treatment protocol for doxorubicin assays. b Micrographs showing a single spheroid at three different drug concentrations for two PDX lines. PH039 showed sensitivity to drug treatment at 0.659 µM, while PH704 sensitivity was lower at the same concentration. Scale bar = 50 µm. c Doxorubicin IC50 curves for sensitive (PH039, IC50–0.659 µM) and resistant (PH704, IC50–4.941 µM) ovarian cancer PDX lines. Red dotted lines denote IC50 values. Black dotted lines represent the viability of the negative control at day 6 (n ≥ 5)
Fig. 6 Drug treatment of cancer cells. a Drug treatment protocol for doxorubicin assays. b Micrographs showing a single spheroid at three different drug concentrations for two PDX lines. PH039 showed sensitivity to drug treatment at 0.659 µM, while PH704 sensitivity was lower at the same concentration. Scale bar = 50 µm. c Doxorubicin IC50 curves for sensitive (PH039, IC50–0.659 µM) and resistant (PH704, IC50–4.941 µM) ovarian cancer PDX lines. Red dotted lines denote IC50 values. Black dotted lines represent the viability of the negative control at day 6 (n ≥ 5)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 109

Metadata

Authors
Dadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A.
Affiliations
Mayo Clinic (US)
Corresponding author
  • Stybayeva, Gulnaz
  • Revzin, Alexander
Venue
Microsystems & Nanoengineering
Published
2020-10-19
Volume
6
Issue
1
Pages
93-93
ISSN
2055-7434 (ISSN-L)
OpenAlex
W3094421561
Cited by
99
References
42
Citations by year
2026: 10 · 2025: 15 · 2024: 25 · 2023: 23 · 2022: 15 · 2021: 11
FWCI
3.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Microsystems & Nanoengineering (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Mayo Clinic (P50- CA136393, CA136393)
  • National Institutes of Health (CA136393)
  • National Cancer Institute (R21CA236612, P50CA136393)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
Keywords
microfluidics, cancer cell spheroids, high-grade serous ovarian cancer, patient-derived xenografts, precision oncology, microvalves, fine-needle aspiration, 3D cell culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. https://app.cochat.ai/papers/10.1038/s41378-020-00201-6
The paper
Dadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A. (2020). A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. Microsystems & Nanoengineering. https://doi.org/10.1038/s41378-020-00201-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.